Metformin Targets Core Aging Pathways Making It a Leading Geroprotective Drug
A 2025 review reveals how metformin's AMPK activation and mitochondrial effects may slow aging beyond its diabetes role.
Summary
Metformin, long used to treat type 2 diabetes, is attracting serious attention in longevity science. A 2025 review from the University of Novi Sad synthesizes evidence showing metformin acts on several molecular hallmarks of aging. By activating AMPK and inhibiting mitochondrial Complex I, the drug reduces oxidative stress, dampens chronic inflammation, promotes autophagy, and limits cellular senescence. These mechanisms translate into measurable protective effects against cardiovascular disease, neurodegeneration, and cancer in preclinical and clinical studies. Combined with its decades-long safety record, low cost, and wide availability, metformin is increasingly positioned as a frontline candidate for geroprotective therapy — potentially slowing biological aging itself rather than just managing individual diseases.
Detailed Summary
Aging research has shifted from treating individual diseases to targeting the shared biological processes that drive them. Metformin, a biguanide drug prescribed for type 2 diabetes since the 1950s, has emerged as one of the most promising candidates for this broader geroprotective role. A 2025 narrative review published in Pharmazie synthesizes current evidence on how metformin influences the molecular machinery of aging.
Researchers from the University of Novi Sad conducted a comprehensive literature review across scientific databases, drawing on in vitro studies, animal models, and clinical data. Their focus was on metformin's biochemical pathways and its impact on age-associated diseases beyond glycemic control.
The review identifies two central mechanisms: activation of AMP-activated protein kinase (AMPK) and inhibition of mitochondrial Complex I. Together these actions reduce reactive oxygen species production, improve mitochondrial efficiency, enhance autophagy, suppress chronic low-grade inflammation, and limit cellular senescence — all recognized hallmarks of biological aging. The authors note that these effects converge on improved metabolic regulation at the cellular level.
Clinically, the evidence points to protective associations with cardiovascular disease, neurodegenerative conditions, and cancer — disorders that collectively define the burden of aging. Metformin's long safety profile, minimal serious side effects, and low cost strengthen the case for studying it as a broadly applicable longevity intervention. The ongoing TAME (Targeting Aging with Metformin) trial is expected to provide pivotal human evidence.
Caveats exist. This is a narrative review without meta-analytic rigor, and much mechanistic evidence comes from animal or cell studies. Optimal dosing for geroprotection versus diabetes management may differ. Nonetheless, metformin stands out among candidate longevity drugs for the depth and breadth of its supporting evidence.
Key Findings
- Metformin activates AMPK and inhibits mitochondrial Complex I, two central anti-aging mechanisms.
- The drug reduces reactive oxygen species production and enhances autophagy, counteracting cellular aging.
- Metformin suppresses chronic inflammation and cellular senescence, key hallmarks of biological aging.
- Protective effects observed across cardiovascular disease, neurodegeneration, and cancer in reviewed studies.
- Low toxicity, cost-effectiveness, and decades of clinical use support metformin's geroprotective potential.
Methodology
This is a narrative literature review, not an original study. Authors searched scientific databases to synthesize findings from in vitro, in vivo, and clinical research on metformin and aging pathways. No systematic review or meta-analytic methodology is described.
Study Limitations
As a narrative review, findings are subject to selection bias and lack the rigor of systematic reviews or meta-analyses. Much mechanistic evidence derives from animal or cell-culture models, limiting direct translation to human aging. Optimal dosing, timing, and patient selection for geroprotective use remain undefined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.